The FDA's finalized guidance for psychedelic drug development is an important milestone, but it also raises a broader question. Can a medical model designed for conventional pharmacology fully evaluate therapies that may transform meaning, relationships, identity, and consciousness? This article explores how psychedelic medicine may invite us to expand, rather than abandon, the medical model.

New COMP360 psilocybin durability data in treatment-resistant depression are encouraging, but durability is not the same as cure. Dr. McCall explores what these findings can and cannot tell clinicians about efficacy, safety, relapse, retreatment, and real-world implementation.

New Phase 3 LSD depression data are encouraging, but they are not the same as FDA approval or broad clinical readiness. Dr. McCall explores why promising psychedelic research needs careful interpretation and clinical humility.

Psychedelic safety is often discussed after something goes wrong. But in responsible clinical care, safety begins much earlier, with screening, preparation, support, and humility.